These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 38049773)

  • 1. Cost-utility and budget impact analyses of cervical cancer screening using self-collected samples for HPV DNA testing in Thailand.
    Kositamongkol C; Kanchanasurakit S; Mepramoon E; Talungchit P; Chaopotong P; Kengkla K; Chaisathaphol T; Saokaew S; Phisalprapa P
    BMC Public Health; 2023 Dec; 23(1):2413. PubMed ID: 38049773
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic evaluation of policy options for prevention and control of cervical cancer in Thailand.
    Praditsitthikorn N; Teerawattananon Y; Tantivess S; Limwattananon S; Riewpaiboon A; Chichareon S; Ieumwananonthachai N; Tangcharoensathien V
    Pharmacoeconomics; 2011 Sep; 29(9):781-806. PubMed ID: 21838332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Budget impact analysis of cervical cancer screening in Portugal: comparison of cytology and primary HPV screening strategies.
    Pista A; Costa C; Saldanha C; Moutinho JAF; Moutinho JM; Arrobas F; Catalão C; Kempers J
    BMC Public Health; 2019 Feb; 19(1):235. PubMed ID: 30808324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Accuracy and cost-effectiveness of cervical cancer screening by high-risk human papillomavirus DNA testing of self-collected vaginal samples.
    Balasubramanian A; Kulasingam SL; Baer A; Hughes JP; Myers ER; Mao C; Kiviat NB; Koutsky LA
    J Low Genit Tract Dis; 2010 Jul; 14(3):185-95. PubMed ID: 20592553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Projected cost-effectiveness of repeat high-risk human papillomavirus testing using self-collected vaginal samples in the Swedish cervical cancer screening program.
    Östensson E; Hellström AC; Hellman K; Gustavsson I; Gyllensten U; Wilander E; Zethraeus N; Andersson S
    Acta Obstet Gynecol Scand; 2013 Jul; 92(7):830-40. PubMed ID: 23530870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
    C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
    Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Clinical and Economic Benefits of Co-Testing Versus Primary HPV Testing for Cervical Cancer Screening: A Modeling Analysis.
    Felix JC; Lacey MJ; Miller JD; Lenhart GM; Spitzer M; Kulkarni R
    J Womens Health (Larchmt); 2016 Jun; 25(6):606-16. PubMed ID: 27023044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in Thailand.
    Sharma M; Ortendahl J; van der Ham E; Sy S; Kim JJ
    BJOG; 2012 Jan; 119(2):166-76. PubMed ID: 21481160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of human papillomavirus DNA testing in the United Kingdom, The Netherlands, France, and Italy.
    Kim JJ; Wright TC; Goldie SJ
    J Natl Cancer Inst; 2005 Jun; 97(12):888-95. PubMed ID: 15956650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost effectiveness analysis of HPV primary screening and dual stain cytology triage compared with cervical cytology.
    Termrungruanglert W; Khemapech N; Tantitamit T; Havanond P
    J Gynecol Oncol; 2019 Mar; 30(2):e17. PubMed ID: 30740950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-risk HPV testing on self-sampled versus clinician-collected specimens: a review on the clinical accuracy and impact on population attendance in cervical cancer screening.
    Snijders PJ; Verhoef VM; Arbyn M; Ogilvie G; Minozzi S; Banzi R; van Kemenade FJ; Heideman DA; Meijer CJ
    Int J Cancer; 2013 May; 132(10):2223-36. PubMed ID: 22907569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance.
    Kim JJ; Wright TC; Goldie SJ
    JAMA; 2002 May; 287(18):2382-90. PubMed ID: 11988059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic Evaluation of Cervical Cancer Screening by HPV DNA, VIA, and Pap smear Methods in Indonesia.
    Hafidz F; Icanervilia AV; Rizal MF; Listiani P; Setyaningsih H; Sasanti ML; Ekawati FM; Atthobari JA; Utami TW; Trirahmanto A; Tjokroprawiro BA; Harsono AB; Masytoh LS; Haryani W; Subekti Y; Nadjib M
    Asian Pac J Cancer Prev; 2024 Sep; 25(9):3015-3022. PubMed ID: 39342578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The budget impact of cervical cancer screening using HPV primary screening.
    Wright T; Huang J; Baker E; Garfield S; Hertz D; Cox JT
    Am J Manag Care; 2016 Mar; 22(3):e95-105. PubMed ID: 26978241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Organised screening for cervical cancer in France: a cost-effectiveness assessment.
    Barré S; Massetti M; Leleu H; De Bels F
    BMJ Open; 2017 Oct; 7(10):e014626. PubMed ID: 28988162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HPV testing compared with routine cytology in cervical screening: long-term follow-up of ARTISTIC RCT.
    Gilham C; Sargent A; Kitchener HC; Peto J
    Health Technol Assess; 2019 Jun; 23(28):1-44. PubMed ID: 31219027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Health technology assessment report: HPV DNA based primary screening for cervical cancer precursors].
    Ronco G; Biggeri A; Confortini M; Naldoni C; Segnan N; Sideri M; Zappa M; Zorzi M; Calvia M; Accetta G; Giordano L; Cogo C; Carozzi F; Gillio Tos A; Arbyn M; Mejier CJ; Snijders PJ; Cuzick J; Giorgi Rossi P
    Epidemiol Prev; 2012; 36(3-4 Suppl 1):e1-72. PubMed ID: 22828243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer.
    Wright TC; Denny L; Kuhn L; Pollack A; Lorincz A
    JAMA; 2000 Jan; 283(1):81-6. PubMed ID: 10632284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of detection rate of high risk HPV infection between self-collected HPV testing and clinician-collected HPV testing in cervical cancer screening.
    Nutthachote P; Oranratanaphan S; Termrungruanglert W; Triratanachat S; Chaiwongkot A; Baedyananda F; Bhattarakosol P
    Taiwan J Obstet Gynecol; 2019 Jul; 58(4):477-481. PubMed ID: 31307736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Costs and benefits of different strategies to screen for cervical cancer in less-developed countries.
    Mandelblatt JS; Lawrence WF; Gaffikin L; Limpahayom KK; Lumbiganon P; Warakamin S; King J; Yi B; Ringers P; Blumenthal PD
    J Natl Cancer Inst; 2002 Oct; 94(19):1469-83. PubMed ID: 12359856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.